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For disease outbreak detection, the 
public-health community has historically 
relied on the watchful eyes of doctors 
and other health-care workers, who have 
reported individual cases or clusters of 
cases of particular diseases to health-
care and other authorities. The increased 
availability of electronic health-care 
data, however, raises the possibility of 
more automated and earlier outbreak 
detection and subsequent intervention. 
Besides diagnoses of known diseases, 
pre-diagnostic syndromic indicators—
such as the primary complaints of 
patients coming to the emergency room 
or calling a nurse hotline—are being 
collected in electronic formats and could 
be analyzed if suitable methods existed. 
Martin Kulldorff and colleagues have 
been developing such methods, and now 
report a new and very ﬂ  exible approach 
for prospective infectious disease 
outbreak surveillance.
Their method, which they call the 
“space–time permutation scan statistic,” 
is an extension of a method called scan 
statistic. All previously developed scan 
statistics require either (i) a uniform 
population at risk (with the same 
number of expected disease cases in 
every square kilometer), (ii) a control 
group (such as emergency visits not due 
to the disease of interest), or (iii) other 
data that provide information about the 
geographical and temporal distribution 
of the underlying population at risk, such 
as census numbers. The new method, 
because of a different probability model, 
can be used for the early detection of 
disease outbreaks when only the number 
of cases is available. It also corrects 
for missing data and makes minimal 
assumptions about the spatiotemporal 
characteristics of an outbreak. To make it 
widely accessible, the method has been 
implemented as a feature of the freely 
available SaTScan software. 
In their article, Kulldorff and colleagues 
illustrate the utility of the new method 
by applying it to data collected from 
hospital emergency departments in 
New York City. The researchers analyzed 
diarrhea records from 2002, and did 
both a “residential analysis” (based on 
the home address of the patients) and 
a “hospital analysis” (based on hospital 
locations). The former has more detailed 
geographical information, the latter 
maybe be better able to detect outbreaks 
not primarily related to place of residence 
but, for example, school or workplace. 
They found four highly unusual clusters 
of diarrhea cases, three of which heralded 
citywide gastrointestinal outbreaks due 
to rotavirus and norovirus. 
Since November 2003, the space–time 
permutation scan statistic has been used 
daily to analyze emergency department 
data in New York City in parallel with 
other methods, and it seems to perform 
well. As the authors discuss, as any 
other surveillance method, theirs has 
limitations. Because it adjusts for purely 
temporal clusters, the method can only 
detect outbreaks if they start locally 
(not simultaneously across the entire 
surveillance area). The less geographically 
compact an outbreak is, the less power 
there is to detect it. And some outbreaks, 
for example, those caused by exposure to 
an infectious agent in the subway, will be 
hard to cluster by place of residence or 
choice of emergency department. 
In the present study, Kulldorff and 
colleagues have applied their method 
to infectious disease surveillance in a 
metropolitan area in the United States. 
As they state, however, “the ability to 
perform disease surveillance without 
population-at-risk data is especially 
important in developing countries, where 
these data may be hard to obtain.” 
Kulldorff M, Heffernan R, Hartman J, 
Assunção R, Mostashari F (2005) A space–
time permutation scan statistic for disease 
outbreak detection. DOI: 10.1371/journal.
pmed.0020059
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Acquired resistance to chemotherapy 
is a major obstacle to successful 
cancer treatment. Understanding the 
mechanisms by which tumors become 
resistant to a particular agent is key to 
identifying new drugs or combination 
regimens. 
Kinases are signaling molecules that 
control many aspects of cell behavior, 
including cell proliferation, i.e., whether 
and how fast cells divide. Abnormally 
active kinases promoting tumor growth 
are found in many cancers and are a 
focus of rational cancer drug design. 
One target for kinase inhibitors is the 
epidermal growth factor receptor (EGFR). 
Two EGFR inhibitors, geﬁ  tinib and 
erlotinib, showed therapeutic beneﬁ  ts in 
a subset of patients with non-small cell 
lung cancer. Recent work has helped us 
understand why some patients respond 
and some don’t: responsive tumors 
usually harbor activating mutations in the 
EGFR gene, which somehow make the 
tumors sensitive to treatment. Nearly all 
patients whose tumors initially respond 
to EGFR inhibitors, however, eventually 
become resistant to the drugs and 
progress despite continued therapy. 
William Pao and colleagues examined 
tumors from six patients with non-small 
cell lung cancer who initially responded 
to geﬁ  tinib or erlotinib but subsequently 
relapsed. Tumors from all six patients 
carried activating mutations in the EGFR 
gene. In addition, in three out of the six 
How Tumor Cells Acquire Resistance to Kinase Inhibitors
DOI: 10.1371/journal.pmed.0020074
Synopses of Research Articles
Open access, freely available online
DOI: 10.1371/journal.pmed.0020065.g001
Disease surveillance in New York City
March 2005  |  Volume 2  |  Issue 3  |  e65  |  e74PLoS Medicine  |  www.plosmedicine.org 0174
cases, the resistant tumor cells carried an 
identical second mutation in the EGFR 
gene. Whereas the activating mutation 
was present in tumor cells before 
treatment with erlotinib or geﬁ  tinib, the 
second mutation was not found in pre-
treatment biopsies from these patients, 
nor in over 150 lung cancer samples 
from patients who had not been treated 
with either drug. Additional cell culture 
studies supported the notion that the 
secondary mutation causes resistance to 
geﬁ  tinib or erlotinib. It is clear, though, 
that this is only one mechanism of 
resistance, because in the three other 
cases resistance occurred in the absence 
of the second mutation. What caused 
the resistance in those tumors is not 
known. 
All kinases share some common 
features, and a resistance mutation very 
similar to the one identiﬁ  ed here has 
also been found in other kinase genes 
from tumors with acquired resistance 
to imatinib, another kinase inhibitor. 
As Gary Gilliland and colleagues point 
out in an accompanying Perspective 
(DOI: 10.1371/journal.pmed.0020075), 
the initial identiﬁ  cation three years 
ago of resistance mutations against 
imatinib led to the rapid development 
of alternative kinase inhibitors that work 
even against tumors with the resistance 
mutation. Similarly, the results by Pao 
and colleagues should help researchers 
develop second generation drugs for 
lung cancer.
Pao W, Miller VA, Politi KA, Riely GJ, 
Somwar R, et al. (2005) Acquired resistance 
of lung adenocarcinomas to geﬁ  tinib 
or erlotinib is associated with a second 
mutation in the EGFR kinase domain. DOI: 
10.1371/journal.pmed.0020073
The prevalence of asthma and allergy 
has risen in all industrialized countries 
during recent decades, and there is much 
debate about exposure to pets in early 
life and later development of asthma and 
allergy. Some studies have suggested that 
keeping pets actually protects against 
later allergy—i.e., that early exposure may 
somehow modify an individual’s immune 
system to tolerate speciﬁ  c antigens. 
What might be the mechanism for such 
protection against allergy? One theory of 
how allergies arise is that an imbalance 
in T helper cell subtypes tips the body’s 
immune response towards overreacting 
to a particular antigen. There is some 
evidence that early exposure to high 
natural levels of cat allergens can prevent 
such an inappropriate immune response. 
Other researchers have suggested 
that normally immune responses are 
kept under control by another group 
of T cells—regulatory T cells. The two 
mechanisms may be linked, since 
exposure to high levels of cat allergens 
may induce regulatory T cells.
Various attempts to modify aberrant 
immune responses to speciﬁ  c allergens, 
such as those to cat dander, have been 
made. Investigators have treated patients 
with related molecules, either peptides 
derived from the allergen itself, or much 
smaller peptides produced synthetically. 
Although therapy with peptides seems to 
reduce allergic responses, the mechanism 
of the response to treatment has not 
been clear, in particular, exactly which 
cells, cell surface markers, and cytokines 
are involved in modifying the immune 
response. 
In a paper in this month’s PLoS 
Medicine, Mark Larché and colleagues 
have attempted to dissect out this 
pathway in a group of individuals with 
asthma and allergy to cats. They treated 
the individuals with short synthetic 
peptides derived from the sequence of 
the major cat allergen, Felis domesticus 
allergen 1, and then measured the 
clinical and immunological response to 
allergen. They found that treatment with 
the peptides led to the induction of a 
population of T cells that were capable of 
suppressing the proliferation of allergen-
reactive T cells in vitro. Peptide treatment 
also resulted in increased levels of a 
molecule called CD5 on the surface 
of blood T cells—CD5 has recently 
been associated with suppressing T 
cell sensitivity to stimulation. Finally, 
the authors found that the degree of 
suppression was not related to the 
amount of peptide given to the patients.
Where does this ﬁ  nding leave patients 
who might wonder about exposure to 
cats and the development of allergy? The 
simple answer is that we do not know 
exactly how exposure to antigen triggers 
either an immune reaction or tolerance. 
Once triggered, an immune reaction 
to a cat may be hard—though not 
impossible—to reverse, but how or why a 
speciﬁ  c individual becomes sensitized is 
as yet far from clear. 
Verhoef A, Alexander C, Kay AB, Larché 
M (2005) T cell epitope immunotherapy 
induces a CD4+ T cell Population with 
regulatory activity. DOI: 10.1371/journal.
pmed.0020078
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What is the level of medical evidence 
that should be used to inform medical 
practice? At the bottom of the hierarchy 
of evidence are anecdotes, expert 
opinion, case reports, and case series, 
and at the top is the systematic review of 
published (and sometimes unpublished) 
evidence. By necessity, systematic reviews 
come many years after hypotheses 
are ﬁ  rst raised, and in the interim 
recommendations for practice may sway 
back and forth. One example of this is 
the debate over the role of uric acid in 
heart disease, which has been going on 
for more than 50 years. It started with a 
paper published in 1951 in the Annals of 
Internal Medicine that found higher serum 
uric acid concentrations in patients with 
coronary heart disease (CHD) compared 
with controls. Since then, measurement of 
serum uric acid has been suggested as a 
predictor of CHD. But many of the studies 
on serum uric acid are epidemiologic 
studies—somewhere in the middle of the 
hierarchy of evidence—and have come 
to different conclusions about how useful 
measurement of uric acid is.
Dissecting out the role of uric 
acid is further complicated by three 
things: high levels of uric acid are 
associated with hypertension and being 
overweight (other risk factors for CHD); 
levels of uric acid can be altered by 
drugs such as diuretics that people with 
CHD often take; and ﬁ  nally, alteration 
of renal function can affect uric acid 
levels. Another problem is the type of 
studies that have been used to address 
the question of uric acid’s role in CHD. 
Retrospective studies may be unable 
to control adequately for other risk 
factors—hence prospective, ideally 
population-based, studies would be the 
best to answer the question of whether 
there really is an association between 
high uric acid and CHD.
In this month’s PLoS Medicine, John 
Danesh and colleagues from the 
University of Cambridge, along with 
investigators from the Icelandic Heart 
Association, report the single largest 
prospective study addressing the role 
of uric acid in heart disease. Further, 
their systematic review combines their 
ﬁ  ndings with those of 15 previously 
published prospective studies of serum 
uric acid—9,458 cases of CHD and 
155,084 controls in all..
The paper answers the question of 
the role of uric acid in prediction of CHD 
clearly: the risk ratio for prediction of 
disease was 1.13 (1.07–1.20), but it was 
only 1.02 (0.91–1.14) in the eight studies 
that had the most complete adjustment 
for possible confounders. What this 
paper does not do is directly address the 
question of whether or not serum uric 
acid is involved in causing CHD through 
intermediates; however, it does suggest 
that serum uric acid levels are unlikely to 
be a major determinant of CHD.
Where does such a result leave 
patients? Well, it is likely that improving 
diet, losing weight, and controlling blood 
pressure may all contribute to reducing 
both one’s risk of CHD and one’s serum 
levels of uric acid. The role of uric acid in 
CHD is now likely to be of interest only to 
those studying basic science; for now, the 
clinical question seems closed. 
Wheeler JG, Juzwishin KDM, Eiriksdottir 
G, Gudnason V, Danesh J (2005) Serum 
uric acid and coronary heart disease in 
9,458 incident cases and 155,084 controls: 
Prospective study and meta-analysis. DOI: 
10.1371/journal.pmed.0020076
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What holds cells together or connects them with the 
extracellular matrix—and what happens when these interactions 
break down—is one of the keys to determining how tumors 
metastasize. One group of compounds—integrins—are a 
central part of these interactions. Not only do integrins play 
a part in cell–cell and cell–matrix adhesion, but they also are 
involved in signal transduction (the method by which a cell 
relays information from receptor binding to cellular response) 
and in triggering cell death by linking to other molecules. One 
such member of this receptor family is the αvβ3 integrin, which 
is expressed on both the tumor cells and the new vasculature 
of various tumors, including melanomas. αvβ3 integrin has a 
role in cell migration and extravasation, which occurs during 
metastasis, and also in angiogenesis—the development of new 
blood vessels that are essential for the growth of tumors. These 
blood vessels are the target for one class of anti-cancer drugs—
angiogenesis inhibitors. Molecules that bind to αvβ3 integrin 
have also been used to target therapeutic compounds to tumors: 
compounds that antagonize this integrin can lead to apoptosis 
(programmed cell death) of cells that express it. 
Haubner and colleagues, the authors of a paper in this month’s 
PLoS Medicine, have previously developed a ﬂ  uorine-labeled 
peptide, [18F]Galacto-RGD, that has a high afﬁ  nity for αvβ3 
integrin. [18F]Galacto-RGD has many of the features essential for a 
tracer: it is speciﬁ  cally accumulated by tumors that express αvβ3 
integrin, it is efﬁ  ciently eliminated by the kidneys, and it is stable 
in vitro and in vivo. 
In the research paper in PLoS Medicine, Haubner and 
colleagues take the development of the compound further 
towards clinical application. First, in a mouse with human 
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melanoma they used highly sensitive positron emission 
tomography (PET) scanning to show not only that the level 
of uptake of integrin was speciﬁ  c for the tumor, but also that 
the uptake was in direct proportion to the amount of αvβ3 
expressed, thus potentially allowing quantiﬁ  cation of receptor 
expression; however, larger tumors showed a poorer correlation, 
possibly because of the presence of necrotic areas that do not 
express the integrin. 
In humans, this picture was a little less clear; in a small study 
of patients with tumors including melanoma, the authors 
found a good deal of difference between patients in the uptake 
of the marker by tumor cells and the corresponding tumor 
vasculature. However, there was good correlation between the 
tracer uptake and conventional staining for the integrin by 
immunohistochemistry—again suggesting that the marker is 
truly reﬂ  ecting the in vivo level of the integrin. 
What do these results mean for clinical applications? As well 
as identifying tumors that express this marker, this approach 
might also offer a noninvasive way to assess the degree of 
new vessel formation in tumors. The approach could provide 
important information for planning and monitoring anti-
angiogenic therapies targeting this integrin and could reveal 
the involvement and role of this integrin in metastatic and 
angiogenic processes in various diseases. 
Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, et al. (2005) 
Noninvasive visualization of the activated αvβ3 integrin in cancer 
patients by positron emission tomography and [18F]Galacto-RGD. 
DOI: 10.1371/journal.pmed.0020070
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